Meningiomas are the most common primary brain tumors and present unique diagnostic challenges due to their diverse morphologic features and behavior. Somatostatin receptor (SSTR) PET imaging promises to address these hurdles and bolster the comprehensive management of meningioma. By leveraging the high SSTR expression of meningiomas, SSTR PET can provide superior sensitivity for diagnosis, delineation of tumor extent, and guidance for surgical and radiation planning, particularly in complex cases involving bone or the skull base. As evidence grows, SSTR PET may also provide insights into prognosis, with uptake patterns potentially correlating with recurrence risk and treatment response. Two illustrative cases from the authors' institution are discussed that demonstrate how SSTR PET influenced both diagnosis and treatment strategy.
Jain et al. (Wed,) studied this question.